Early progression of disease as a predictor of survival in chronic lymphocytic leukemia

Authors :: Neil E. Kay
Charles M. Farber
Jeff P. Sharman
Kristen A. Sullivan
E. Dawn Flick
Pavel Kiselev
Arlene S. Swern
Anthony R. Mato
Matthew S. Davids
Nicole Lamanna
David L. Grinblatt
Christopher R. Flowers
Inhye E. Ahn
Chadi Nabhan
Source :: Blood Advances. 1:2433-2443
Publication Year :: 2017
Publisher :: American Society of Hematology, 2017.
Abstract: Chemoimmunotherapy for chronic lymphocytic leukemia (CLL) promotes clonal evolution of aggressive clones, which in some patients may lead to early progression of disease (POD). We studied the prognostic value of early POD in a cohort of patients with CLL enrolled between 2010 and 2014 in the Connect CLL Registry. Overall, 829 eligible patients receiving first-line therapy were categorized into 3 groups: early POD (progression

Tools